This issue of Hematology/Oncology Clinics of North America, devoted to Colorectal Cancer, is edited by Dr. Leonard B. Saltz. Articles in this issue include: Diet and Lifestyle Influences on Colorectal Cancer; Diagnosis and Management of Germline and Somatic Mutations in Mismatch Repair-deficient Colorectal Cancer; Adjuvant Chemotherapy in Stage II, III, and Resected Stage IV Colon Cancer; Predictive and Prognostic Markers in the Treatment of Colorectal Cancer; Surgical Management of Hepatic Metastases of Colorectal Cancer; Combination Therapies in Colorectal Cancer Treatment; A Critical Look at Management of Peritoneal Metastases of Colorectal Cancer; Non-surgical Management of Rectal Cancer; and Ablative Therapies for Metastatic Colorectal Cancer.

The rapid growth in the number of options available for the management of colorectal cancer presents the clinician with new opportunities and new complexities. An explosion of understanding in the basic science that underlies both the disease and its potential therapies has translated into remarkable technological advances that can now be applied. So many specialties and subspecialties have now been brought to bear that it is appropriate to attempt to bring the expertise from these areas together in one volume, so that practitioners in one aspect of colorectal cancer management can maintain knowledge and expertise regarding the capabilities of other colleagues working in this disease. Colo rectal Cancer: Multimodality Management provides a concise, focused, and current review of the methodological and technological advances that have recently occurred in the management of colorectal cancer. The book has been divided into six basic parts. The first part, dealing with epidemiology and prevention, focuses on the molecular genetic events that occur in the development of colorectal cancer, as well as on our understanding of dietary and environmental factors, and possible strategies for prevention. Part II focuses on both diagnos­ tic and therapeutic radiology in the management of colorectal cancer, dealing with innumer­ able advances in imaging, and with the progress in the science and art of radiation therapy. The third section deals with the surgical aspects of management of colorectal cancer, starting with surgical pathology.

The rapid growth in the number of options available for the management of colorectal cancer presents the clinician with new opportunities and new complexities. An explosion of understanding in the basic science that underlies both the disease and its potential therapies has translated into remarkable technological advances that can now be applied. So many specialties and subspecialties have now been brought to bear that it is appropriate to attempt to bring the expertise from these areas together in one volume, so that practitioners in one aspect of colorectal cancer management can maintain knowledge and expertise regarding the capabilities of other colleagues working in this disease. Colo rectal Cancer: Multimodality Management provides a concise, focused, and current review of the methodological and technological advances that have recently occurred in the management of colorectal cancer. The book has been divided into six basic parts. The first part, dealing with epidemiology and prevention, focuses on the molecular genetic events that occur in the development of colorectal cancer, as well as on our understanding of dietary and environmental factors, and possible strategies for prevention. Part II focuses on both diagnos­ tic and therapeutic radiology in the management of colorectal cancer, dealing with innumer­ able advances in imaging, and with the progress in the science and art of radiation therapy. The third section deals with the surgical aspects of management of colorectal cancer, starting with surgical pathology.

Management options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development. Likewise, surgical and ablative options, as well as an array of supportive medications, have shown substantial progress and undergone a dramatic proliferation over the past decade. With the increased number of therapeutic options from which to choose, the clinician is better able to offer effective therapy to the patient with colorectal cancer. The clinician is challenged, however, to keep up with the rapidly changing landscape and the rapidly emerging data that shape the options for treatment today and tom- row. In this text, leaders in the management of colorectal cancer review the current literature that has led us to where we are today. Critical evaluations of the data are offered, and evidence-based recommendations are made.

The rapid growth in the number of options available for the management of colorectal cancer presents the clinician with new opportunities and new complexities. An explosion of understanding in the basic science that underlies both the disease and its potential therapies has translated into remarkable technological advances that can now be applied. So many specialties and subspecialties have now been brought to bear that it is appropriate to attempt to bring the expertise from these areas together in one volume, so that practitioners in one aspect of colorectal cancer management can maintain knowledge and expertise regarding the capabilities of other colleagues working in this disease. Colo rectal Cancer: Multimodality Management provides a concise, focused, and current review of the methodological and technological advances that have recently occurred in the management of colorectal cancer. The book has been divided into six basic parts. The first part, dealing with epidemiology and prevention, focuses on the molecular genetic events that occur in the development of colorectal cancer, as well as on our understanding of dietary and environmental factors, and possible strategies for prevention. Part II focuses on both diagnos­ tic and therapeutic radiology in the management of colorectal cancer, dealing with innumer­ able advances in imaging, and with the progress in the science and art of radiation therapy. The third section deals with the surgical aspects of management of colorectal cancer, starting with surgical pathology.

Management options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development. Likewise, surgical and ablative options, as well as an array of supportive medications, have shown substantial progress and undergone a dramatic proliferation over the past decade. With the increased number of therapeutic options from which to choose, the clinician is better able to offer effective therapy to the patient with colorectal cancer. The clinician is challenged, however, to keep up with the rapidly changing landscape and the rapidly emerging data that shape the options for treatment today and tom- row. In this text, leaders in the management of colorectal cancer review the current literature that has led us to where we are today. Critical evaluations of the data are offered, and evidence-based recommendations are made.

This issue of Hematology/Oncology Clinics of North America, devoted to Colorectal Cancer, is edited by Dr. Leonard B. Saltz. Articles in this issue include: Diet and Lifestyle Influences on Colorectal Cancer; Diagnosis and Management of Germline and Somatic Mutations in Mismatch Repair-deficient Colorectal Cancer; Adjuvant Chemotherapy in Stage II, III, and Resected Stage IV Colon Cancer; Predictive and Prognostic Markers in the Treatment of Colorectal Cancer; Surgical Management of Hepatic Metastases of Colorectal Cancer; Combination Therapies in Colorectal Cancer Treatment; A Critical Look at Management of Peritoneal Metastases of Colorectal Cancer; Non-surgical Management of Rectal Cancer; and Ablative Therapies for Metastatic Colorectal Cancer.

The rapid growth in the number of options available for the management of colorectal cancer presents the clinician with new opportunities and new complexities. An explosion of understanding in the basic science that underlies both the disease and its potential therapies has translated into remarkable technological advances that can now be applied. So many specialties and subspecialties have now been brought to bear that it is appropriate to attempt to bring the expertise from these areas together in one volume, so that practitioners in one aspect of colorectal cancer management can maintain knowledge and expertise regarding the capabilities of other colleagues working in this disease. Colo rectal Cancer: Multimodality Management provides a concise, focused, and current review of the methodological and technological advances that have recently occurred in the management of colorectal cancer. The book has been divided into six basic parts. The first part, dealing with epidemiology and prevention, focuses on the molecular genetic events that occur in the development of colorectal cancer, as well as on our understanding of dietary and environmental factors, and possible strategies for prevention. Part II focuses on both diagnos­ tic and therapeutic radiology in the management of colorectal cancer, dealing with innumer­ able advances in imaging, and with the progress in the science and art of radiation therapy. The third section deals with the surgical aspects of management of colorectal cancer, starting with surgical pathology.

The rapid growth in the number of options available for the management of colorectal cancer presents the clinician with new opportunities and new complexities. An explosion of understanding in the basic science that underlies both the disease and its potential therapies has translated into remarkable technological advances that can now be applied. So many specialties and subspecialties have now been brought to bear that it is appropriate to attempt to bring the expertise from these areas together in one volume, so that practitioners in one aspect of colorectal cancer management can maintain knowledge and expertise regarding the capabilities of other colleagues working in this disease. Colo rectal Cancer: Multimodality Management provides a concise, focused, and current review of the methodological and technological advances that have recently occurred in the management of colorectal cancer. The book has been divided into six basic parts. The first part, dealing with epidemiology and prevention, focuses on the molecular genetic events that occur in the development of colorectal cancer, as well as on our understanding of dietary and environmental factors, and possible strategies for prevention. Part II focuses on both diagnos­ tic and therapeutic radiology in the management of colorectal cancer, dealing with innumer­ able advances in imaging, and with the progress in the science and art of radiation therapy. The third section deals with the surgical aspects of management of colorectal cancer, starting with surgical pathology.

Management options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development. Likewise, surgical and ablative options, as well as an array of supportive medications, have shown substantial progress and undergone a dramatic proliferation over the past decade. With the increased number of therapeutic options from which to choose, the clinician is better able to offer effective therapy to the patient with colorectal cancer. The clinician is challenged, however, to keep up with the rapidly changing landscape and the rapidly emerging data that shape the options for treatment today and tom- row. In this text, leaders in the management of colorectal cancer review the current literature that has led us to where we are today. Critical evaluations of the data are offered, and evidence-based recommendations are made.

The rapid growth in the number of options available for the management of colorectal cancer presents the clinician with new opportunities and new complexities. An explosion of understanding in the basic science that underlies both the disease and its potential therapies has translated into remarkable technological advances that can now be applied. So many specialties and subspecialties have now been brought to bear that it is appropriate to attempt to bring the expertise from these areas together in one volume, so that practitioners in one aspect of colorectal cancer management can maintain knowledge and expertise regarding the capabilities of other colleagues working in this disease. Colo rectal Cancer: Multimodality Management provides a concise, focused, and current review of the methodological and technological advances that have recently occurred in the management of colorectal cancer. The book has been divided into six basic parts. The first part, dealing with epidemiology and prevention, focuses on the molecular genetic events that occur in the development of colorectal cancer, as well as on our understanding of dietary and environmental factors, and possible strategies for prevention. Part II focuses on both diagnos­ tic and therapeutic radiology in the management of colorectal cancer, dealing with innumer­ able advances in imaging, and with the progress in the science and art of radiation therapy. The third section deals with the surgical aspects of management of colorectal cancer, starting with surgical pathology.

Management options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development. Likewise, surgical and ablative options, as well as an array of supportive medications, have shown substantial progress and undergone a dramatic proliferation over the past decade. With the increased number of therapeutic options from which to choose, the clinician is better able to offer effective therapy to the patient with colorectal cancer. The clinician is challenged, however, to keep up with the rapidly changing landscape and the rapidly emerging data that shape the options for treatment today and tom- row. In this text, leaders in the management of colorectal cancer review the current literature that has led us to where we are today. Critical evaluations of the data are offered, and evidence-based recommendations are made.